title: Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine.
abstract: OBJECTIVE
  To identify the factors associated with virologic breakthrough and to select a subgroup of patients who respond well to lamivudine without developing virologic breakthrough (VBT).
  
  
  METHODS
  Of 79 patients who had received lamivudine therapy for 9-57 mo, 34 were HBeAg-positive and 45 were HBeAg-negative, 24 developed virologic breakthrough and 55 did not. Clinical and virologic factors were compared between the two groups.
  
  
  RESULTS
  The median duration of therapy was 25 (9-57) mo. Virologic breakthrough was defined as a > 1 log HBV DNA increase following initial suppression. When several factors, including gender, duration of infection, baseline HBV DNA, and baseline ALT in HBeAg-positive chronic hepatitis patients were analyzed by logistic regression, the most important predictor of virologic breakthrough was the baseline HBV DNA (r2 = 0.12, P < 0.05). When HBeAg-positive chronic hepatitis patients were divided into two groups by a point of 6.6 log HBV DNA, the incidence of virologic breakthough between two groups was significantly different.
  
  
  CONCLUSIONS
  Lamivudine may remain an effective first line therapy for those HBeAg-positive patients with a baseline HBV DNA < 6.6 log10 copies/mL.
authors: Liver Disease Prevention Center, Division of Gastroenterology and Hepatology, Department of Medicine, Jefferson Medical College and Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.
authors: Hee Bok
authors: HB
authors: Chae
authors: Hie-Won
authors: HW
authors: Hann
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D004279:DNA, Viral / Q000097:blood*; D024882:Drug Resistance, Viral; D005260:Female; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000235:genetics* / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000097:blood* / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D014758:Viral Core Proteins / Q000235:genetics; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D006513:Hepatitis B e Antigens; D014758:Viral Core Proteins; D019259:Lamivudine
references: Gut. 2005 Nov;54(11):1610-4
references: 15871997
references: Liver Transpl. 2003 Jan;9(1):49-56
references: 12514773
references: Clin Gastroenterol Hepatol. 2004 Feb;2(2):87-106
references: 15017613
references: J Clin Microbiol. 2002 Oct;40(10):3729-34
references: 12354872
references: J Gastroenterol Hepatol. 2005 Mar;20(3):433-40
references: 15740489
references: Hepatology. 2000 Jan;31(1):207-10
references: 10613747
references: N Engl J Med. 2004 Oct 7;351(15):1521-31
references: 15470215
references: Clin Infect Dis. 2003 Mar 15;36(6):687-96
references: 12627352
references: J Gastroenterol Hepatol. 2004 Nov;19(11):1276-82
references: 15482535
references: Am J Gastroenterol. 2005 Sep;100(9):1984-94
references: 16128943
references: N Engl J Med. 2006 Mar 9;354(10):1001-10
references: 16525137
references: Hepatology. 2002 Oct;36(4 Pt 1):1025-6; author reply 1026
references: 12297859
references: JAMA. 2006 Jan 4;295(1):65-73
references: 16391218
references: J Hepatol. 2001 Jul;35(1):92-8
references: 11495048
references: Gastroenterology. 2003 Dec;125(6):1714-22
references: 14724824
references: Hepatology. 2001 Feb;33(2):424-32
references: 11172345
references: J Hepatol. 2005 Jul;43(1):72-7
references: 15896869
references: N Engl J Med. 2006 Mar 9;354(10):1011-20
references: 16525138